Navigation Links
Gen-Probe Announces Webcast of Second Quarter 2008 Earnings Conference Call
Date:7/10/2008

SAN DIEGO, July 10 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will release its second quarter 2008 financial results on Thursday, July 31, 2008 at approximately 4:00 p.m. Eastern Time (ET). The announcement will be followed by a conference call at 4:30 p.m. ET. Hank Nordhoff, chairman and chief executive officer, and Herm Rosenman, senior vice president, finance, and chief financial officer, will host the call.

The conference call will be webcast live and may be accessed on the investors section of the Company's web site at http://www.gen-probe.com . An archived version of the webcast will be available on the same web site for at least 90 days. A telephone replay also will be available for 24 hours after the call ends. To access the replay, please call 866-447-7331 (U.S.) or 203-369-1162 (international).

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to http://www.gen-probe.com .

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the period ended March 31, 2008, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Paula Izidoro

Investor Relations

858-410-8904

paulai@gen-probe.com


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
2. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
5. Carl Hull Named President and Chief Operating Officer of Gen-Probe
6. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
7. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
8. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
9. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
10. Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference
11. Lucy Shapiro, Ph.D., Elected to Gen-Probe Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Minn. , Feb. 23, 2017  Imanis ... new product line of oncolytic vaccinia viruses for ... Corporation as part of Genelux,s proprietary, vaccinia virus-based ... are excited to enter into a partnership with ... selected oncolytic vaccinia viruses for use in research," ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can fast-track sample ... acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. ... the relationship between insulin and other relevant biomarkers can be extensively studied through ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017 /PRNewswire/ ... and Beyond Type 1, a not-for-profit advocacy and education ... announced a grant from Beyond Type 1 to support ... 1 and other insulin-requiring diabetes.  For ... stem cell-derived cell replacement therapies with a focus on ...
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... ... a free AFM Luncheon for all SPIE attendees and Park ... CA, just one block from the San Jose Convention Center. The luncheon will ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
Breaking Biology News(10 mins):